Highest-materiality recent filing
Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO
Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright for up to $150M of common stock in at-the-market offerings.
Nektar Q1 net loss $44.9M; cash $731.6M; rezpegaldesleukin Phase 3 to start July
Net loss $44.9M ($1.82 loss per share) vs $50.9M in Q1 2025.
Nektar prices $325M upsized equity offering at $92/share; net proceeds ~$350.9M
Firm shares: 3,532,609 at $92.00; underwriters exercised option for 529,891 additional shares in full.
Nektar: REZOLVE-AA 52-wk SALT≤20 at 25.8% (low) and 27.6% (high) vs 6.7% placebo; p=0.049
SALT≤20 responders nearly doubled from week 36: low dose 25.8% (from 14.8%), high dose 27.6% (from 15.6%), placebo unchanged at 6.7%.
Nektar reports Q4 2025 net loss $36.1M ($1.78/sh); cash $245.8M plus $460M Feb 2026 offering
Revenue Q4 2025 $21.8M vs $29.2M YoY; full year $55.2M vs $98.4M.
Nektar Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants
Offering of 6,603,449 common shares at $58.00 and 293,103 pre-funded warrants at $57.9999; gross proceeds $400M.
Nektar REZOLVE-AD maintenance data show durable EASI-75/90, vIGA-AD responses
71% (monthly) and 83% (quarterly) maintained EASI-75 on 24 µg/kg; 85% and 63% maintained vIGA-AD 0/1.
Mean % SALT reduction at Week 36: 28.2% (24 µg/kg), 30.3% (18 µg/kg) vs 11.2% placebo (p=0.186, p=0.121).
Nektar reports REZOLVE-AD Phase 2b data showing asthma improvements with rezpegaldesleukin
Respegaldesleukin achieved statistically significant ACQ-5 reductions vs placebo in patients with AD and asthma (p<0.05).
Nektar Q3 net loss $35.5M ($1.87/sh), revenue $11.8M; cash $270.2M; rezpeg data at ACAAI
Net loss $35.5M ($1.87/sh) vs $37.1M ($2.66/sh) in Q3 2024.
Nektar Phase 2b rezpegaldesleukin meets primary endpoint; EASI-75 66% vs 34% placebo at week 16
All three rezpegaldesleukin dose arms met primary endpoint of mean % EASI improvement at week 16 (p<0.001 vs placebo).
Nektar Q2 net loss $41.6M; rezpegaldesleukin Fast Track; cash runway into Q1 2027
Revenue $11.2M Q2 2025 vs $23.5M Q2 2024; decrease due to sale of Huntsville facility.
Nektar Therapeutics prices $100M public offering at $23.50 per share
Nektar prices 4,255,320 shares at $23.50/share for gross proceeds of $100M.
REZOLVE-AD met primary endpoint: mean EASI improvement from baseline at week 16 for all three rezpegaldesleukin dose arms vs placebo (p<0.001).
Nektar boosts authorized shares to 390M, completes 1-for-15 reverse split effective June 8
Authorized common shares increased from 300M to 390M, effective June 6, 2025, stockholder-approved May 23, 2025.
Nektar Therapeutics announces 1-for-15 reverse stock split effective June 8
Board approved 1-for-15 reverse stock split effective June 8, 2025 at 11:59 p.m. ET.
Nektar Q1 net loss $50.9M, cash $220.7M; Phase 2 data expected June
Cash & marketable securities $220.7M, expected to fund operations into Q4 2026.
Nektar receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq notice on April 3, 2025 for non-compliance with minimum bid price rule.
Nektar enters ATM equity distribution agreement for up to $75M
ATM equity distribution agreement with Piper Sandler and BTIG allows sale of up to $75M of common stock.
Nektar Therapeutics reports Q4 net income $7.3M; rezpegaldesleukin Phase 2b data expected in 2025
Q4 net income $7.3M ($0.03 EPS) vs net loss $42.1M in Q4 2023; full year net loss $119M vs $276.1M.
Nektar CMO Mary Tagliaferri resigns; Brian Kotzin named interim CMO
Mary Tagliaferri resigned as SVP and CMO effective Feb 4, 2025, for personal reasons; no disagreement with company.
Nektar Q3 net loss narrows to $37.1M; sells Huntsville business for $90M
Net loss $37.1M ($0.18/sh) vs $45.8M ($0.24) in Q3 2023; revenue flat at $24.1M.
Nektar to sell Huntsville PEGylation plant to Ampersand for $90M
Total consideration $90M ($70M cash, $20M equity in new Ampersand portfolio co.).
Nektar Q2 net loss $52.4M, cash $290.6M, rezpegaldesleukin Phase 2b on track for H1 2025 topline
Net loss Q2 2024 $52.4M ($0.25/share) vs $51.1M ($0.27) Q2 2023; non-GAAP net loss $39.1M ($0.19).
Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.
On May 7, 2026, the Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026.
Max materiality 0.80 · Median 0.65 · Most common event other_material